Orphazyme-Arimoclomol Phase III Clinical Trial

Apr 11, 2019

Back to Active Studies

Help us determine the safety and efficacy of an ALS drug

Study ended

Study Name
Orphazyme-Arimoclomol Phase III Clinical Trial
PI
Michael Benatar, MD, PhD
Study Type
Interventional (Clinical Trial), Phase 3, Randomized, Double-Blind, Placebo-controlled
Eligible Population

Individuals affected with ALS, with symptoms of weakness appearing less than 18 months prior to enrollment and preserved respiratory function

Study Purpose/Goals

To evaluate the efficacy and safety of arimoclomol in ALS.

A Phase 3, Randomized, Placebo-Controlled Trial of Arimoclomol in Amyotrophic Lateral Sclerosis

Procedures/Participation

82 weeks (~1.5 years) of participation

  • Medical history and medication review
  • Drug dosing with diary tracking
  • Breathing testing
  • Neuropsychological testing
  • Questionnaires/Surveys
  • Physical exam
  • Neurological exam
  • Electrocardiogram
  • Blood, urine, and CSF collection

Links
https://clinicaltrials.gov/ct2/show/NCT03491462?term=A+Phase+3%2C+Randomised%2C+Placebo-Controlled+Trial+of+Arimoclomol+in+Amyotrophic+Lateral+Sclerosis&rank=1

 




Contact
E-mail to Register
Back to Active Studies

Join our family - together, we can change the course of this disease.

Join our family

Together, we can change the course of this disease.

Make a DonationJoin our ResearchAttend an Upcoming Event

Copyright © 2020. ALS Center at the University of Miami. All Rights Reserved. Branding by Mok2